Scholars@Duke

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

Publication ,  Conference
Agarwal, A; MacKenzie, R; Oddo, J; Vitek, MP; Christensen, DJ; Druker, BJ
Published in: Blood
November 18, 2011
Published version (DOI) Publisher Link

Abstract 3757

Duke Scholars

Michael P. Vitek
Author Michael P. Vitek Neurology, Behavioral Neurology

Published In

Blood

DOI

10.1182/blood.v118.21.3757.3757

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 18, 2011

Volume

118

Issue

21

Start / End Page

3757 / 3757

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Agarwal, A., MacKenzie, R., Oddo, J., Vitek, M. P., Christensen, D. J., & Druker, B. J. (2011). A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,. In Blood (Vol. 118, pp. 3757–3757). American Society of Hematology. https://doi.org/10.1182/blood.v118.21.3757.3757
Agarwal, Anupriya, Ryan MacKenzie, Jessica Oddo, Michael P. Vitek, Dale J. Christensen, and Brian J. Druker. “A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,.” In Blood, 118:3757–3757. American Society of Hematology, 2011. https://doi.org/10.1182/blood.v118.21.3757.3757.
Agarwal A, MacKenzie R, Oddo J, Vitek MP, Christensen DJ, Druker BJ. A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,. In: Blood. American Society of Hematology; 2011. p. 3757–3757.
Agarwal, Anupriya, et al. “A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,.” Blood, vol. 118, no. 21, American Society of Hematology, 2011, pp. 3757–3757. Crossref, doi:10.1182/blood.v118.21.3757.3757.
Agarwal A, MacKenzie R, Oddo J, Vitek MP, Christensen DJ, Druker BJ. A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,. Blood. American Society of Hematology; 2011. p. 3757–3757.

Published In

Blood

DOI

10.1182/blood.v118.21.3757.3757

EISSN

1528-0020

ISSN

0006-4971

Publication Date

November 18, 2011

Volume

118

Issue

21

Start / End Page

3757 / 3757

Publisher

American Society of Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology